Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

Inclusion Criteria: * Patients must have a history of uveal melanoma and documented metastatic disease * Patients must have at least one unidimensionally measurable lesion; if this is a cutaneous lesion it must be at least 10 mm by caliper measure; if it is a visceral or nodal or soft tissue lesion, it must be clearly measurable \> 20 mm with conventional techniques or \> 10 mm with spiral CT scan; bone lesions are not considered measurable * One prior systemic chemotherapy and any number of immunotherapies or vaccine therapies are allowed; prior treatment with hepatic arterial chemotherapy infusion or perfusion or chemoembolization of liver metastasis is allowed; prior treatment with radiation therapy is allowed but not more than 3000 cGy to fields including substantial marrow; patients are not required to have had prior therapy * At least 6 weeks (42 days) since any prior immunotherapy, cytokine, biologic, vaccine or other therapy unless patients have progressed during therapy; if progression occurred during therapy, patient must have recovered from any side effects * At least 4 weeks (28 days) since prior radiotherapy and prior adjuvant chemotherapy * Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 * Patients must have a life expectancy of at least 3 months * Leukocytes \> 3,000/mm3 * Absolute neutrophil count ≥ 1,500/mm3 * Hemoglobin ≥ 9.0 g/dL * Platelets ≥ 100,000/mm3 * Aspartate transaminase-alanine transaminase ratio (AST…